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ABSTRACT

Pan, Li. Ph.D., Purdue University, August 2016. Development of Dendrimer-based
Technologies for Phosphoproteomics and Glycoproteomics in Biomarker Discovery.
Major Professor: Weiguo Andy Tao.

The dynamics of post-translational modifications (PTMs) of proteins keeps cells
adapting to the ever-changing microenvironment by regulating protein structure and
function in the real-time mode. Of all PTMs, protein phosphorylation and glycosylation
are undoubtedly two of the most common and important PTMs and have been
demonstrated to be closely linked to the onset and progression of various human
diseases. Our lab has been focusing on developing novel and more efficient technologies
by taking advantage of the properties of dendrimers – a soluble nanopolymer with
chemically well-defined structure and functional surface groups – to facilitate the
detection and quantification of PTMs using several biochemical assays and mass
spectrometry-based shotgun proteomics.
In chapter 2, we present a sensitive phosphorylation assay on a 96-well
microplate to determine total protein phosphorylation level of complex protein samples
calibrated to a phosphoprotein standard. The core of the assay is a reagent termed
pIMAGO that is multi-functionalized with titanium ions for its superior selectivity
towards phosphorylated proteins and with fluorophores for quantification. We

xiv
demonstrated the excellent specificity, sensitivity, and quantitative nature of the assay
with both standard proteins and whole cell lysates. The method was then employed to
measure the overall protein phosphorylation level of human cells under different
treatments. At last, we investigated the practicability of the assay to serve as a sensitive
tool to estimate the amount of phosphorylated samples prior to a mass spectrometrybased phosphoproteomic analysis.
In chapter 3, we introduce the multiplexed quantitation of phosphorylation and
protein expression based on pIMAGO. The nanopolymer allows for direct competition
for epitopes on proteins of interest, thus facilitating simultaneous detection of
phosphorylation by pIMAGO and total protein amount by protein antibody in the same
well of microplates. This new strategy allows us to measure cell signaling events by
clearly distinguishing actual phosphorylation signals from protein expression changes,
thus providing a powerful tool to accurately profile cellular signal transduction in
healthy and disease cells.
In chapter 4, we devise a completely novel platform to capture and profile
glycoproteome, termed polymer-based reverse phase GlycoProtein Array (polyGPA).
Nitrocellulose membranes pre-coated with dendrimers functionalized with
hydroxylamine groups were used to covalently capture pre-oxidized glycans on
glycoproteins from whole protein extracts or biofluids. The captured glycoproteins can
then be detected using the same validated antibodies as in standard reverse phase
protein array (RPPA). We demonstrated the outstanding specificity, sensitivity, and
quantitative capabilities of polyGPA by capturing and detecting the alpha-1-acid

xv
glycoprotein (AGP) standard as well as endogenous AGP in human plasma. We then
applied the strategy to validate a panel of potential biomarkers for bladder cancer
identified by performing comparative N-glycoproteomics of urinary microvesicles from
healthy control volunteers and bladder cancer patients and label-free quantification.

1

CHAPTER 1.

1.1

INTRODUCTION

Current methods for detection and quantification of protein phosphorylation
Protein phosphorylation is one of the most important post-translational

modifications and plays a crucial role in the regulation of nearly every aspect of cellular
life.1 Thus, detection of protein phosphorylation, especially quantitative measurement
of changes in protein phosphorylation, is essential for a better understanding of how
signaling pathways function in cells under both normal and diseased states.2 While
many researchers focus on specific proteins and phosphorylation events, global analysis
of protein phosphorylation in the whole cell or in protein complexes could be as
beneficial.
Many biological experiments frequently require the estimation of total protein
amount. However, the estimation of total protein phosphorylation level in biological
samples, while equivalently important, has seldom been practiced. This is largely due to
the fact that current method for phosphorylation measurement is neither convenient
nor sensitive. Existing methods for global phosphorylation analyses include the use of
32P

radioactive labeling, molybdate-based colorimetric determination, phospho-specific

antibodies, phospho-staining reagents, or high performance mass spectrometry. One of
the major limitations of the classic radioactive labeling with 32P-orthophosphate, in
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addition to its safety issues, is that long-time incubations of whole cells with large doses
of radioisotopes are very toxic in nature, leading to DNA damage, cell cycle arrest, and
eventually apoptosis.3,4 Thus, it has nowadays more commonly been used to detect the
phosphorylation of protein substrates in in vitro kinase assays. Molybdate colorimetric
method is based on the alkaline hydrolysis of phosphate from seryl and threonyl
residues and quantification of the released phosphate with malachite green and
ammonium molybdate.5 It has been applied to the estimation of the phosphate content
of purified samples or the staining of proteins separated by polyacrylamide gel
electrophoresis (SDS-PAGE).5,6 However, the detection is indirect, relatively insensitive,
and most of all, limited to proteins that are phosphorylated at serine or threonine
residues.6 Antibodies such as anti-phosphotyrosine antibodies have facilitated the
detection of total tyrosine phosphorylation in protein complexes, but these antibodies
are still sequence-dependent.7-9 Moreover, at present there is still no reliable antibody
available that can recognize serine- and threonine-phosphorylated proteins,
independent of sequences. To overcome the limitations of antibodies, there have been
attempts recently in applying novel chemical reagents to staining phosphoproteins in
gels or on membrane, including Phos-tag, Pro-Q Diamond, Stains-All and other similar
reagents or methods.10-15 These staining techniques are most useful for qualitative
detection of protein phosphorylation by mobility shift or relative measurement of
phosphorylation changes in individual protein bands after separation in one- or twodimensional gels.16-18 Besides, there are methods specifically developed to measure the
activities of kinases or phosphatases, such as ADP-Glo kinase assay, Omnia kinase assay,
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and IMAP FP kinase and phosphatase assays.19-22 However, all these methods are
devised to measure phosphorylation or dephosphorylation on specific proteins or
peptides.
In the past decade, mass spectrometry has evolved into a powerful tool for
large-scale analysis of proteins and post-translational modifications, including the
identification of novel phosphorylated proteins and phosphorylation sites.23-25
Challenges still remain due to the relatively low stoichiometric nature and ionization
efficiency of phosphopeptides, so additional steps for phosphopeptide enrichment are
usually required.25,26 Furthermore, samples for mass spectrometric analyses often vary
significantly in terms of the protein phosphorylation level. Samples extracted from yeast
and plant cells, for instance, have typically much lower levels of phosphorylation than
those from human cells with the same total amount of proteins. Thus, a larger starting
amount is desirable for phosphoproteomic studies with yeast or plant samples. The
exact sample amount to be used, however, is mostly judged by individual laboratories
based on either previous reports or trial-and-error experiments. Therefore, it would be
extremely useful to develop a simple and sensitive assay to measure total protein
phosphorylation level in individual samples, in analogy to the bicinchoninic acid (BCA)
protein assay.
1.2

Current strategies for profiling protein glycosylation in biomarker discovery
Protein glycosylation is the most structurally complex form of post-translational

modifications of proteins and the structural complexity of protein glycosylation plays an
essential role in a diverse range of biological processes.27-29 Aberrant glycosylation has
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been found closely associated with various cancers, inflammatory and degenerative
diseases, etc. Thus, profiling of protein glycosylation in search of potential disease
biomarkers has remained as a primary interest of biomedical research.
In the past decades, mass spectrometry (MS) has been the driving force in
profiling glycoproteomes for biomarker research. Due to the extreme heterogeneity of
glycoproteins and the wide dynamic range of proteins present in clinical samples, it is
still very challenging to comprehensively characterize glycoproteins by mass
spectrometry, especially for clinical studies.30,31 Change in glycosylation in cancer cells
can be either the abundance of glycosylated proteins, or the glycosite occupancy, or the
structure of glycans on individual sites, and most likely a combination of all three. Most
mass spectrometry-based strategies focus on one or two factors.
Nevertheless, before mass spectrometric analysis, it is always necessary to
simplify a complex crude sample by enriching either glycoproteins or glycopeptides or at
both levels. Two of the most commonly used methods are lectin affinity
chromatography (LAC) and hydrazide chemistry-based capture. Lectins are
carbohydrate-binding proteins. There are more than 160 lectins known and over 60 are
commercially available with either broad or narrow specificity towards a certain group
of glycans.32 LAC-based enrichment of glycoproteins or glycopeptides can be followed by
mass spectrometric analysis for the identification of glycoproteins and glycosylation
sites or for the characterization of glycans significantly changed in cancers. 33,34 However,
the selectivity of lectins make them impossible to bind the entire glycoproteome, thus
preventing LAC from becoming an un-biased way of enrichment. Compared to LAC,
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hydrazide capture, another commonly used strategy for the enrichment of glycoproteins
or glycopeptides, is through non-specifically and covalently coupling aldehyde groups on
periodate-oxidized glycans to a solid phase with immobilized hydrazide groups.35 Since
the hydrazide capture is nondiscriminatory, it can be used to bind the entire
glycoproteome. However, the structure of glycans is damaged during oxidation and only
glycosite-containing peptides are released for proteomic analysis by mass spectrometry.
Finally, the generated MS/MS spectral data rely heavily on bioinformatics software to
determine protein identification, peptide sequence with glycosylation sites, glycan
structure, and quantitative information, which itself is still a huge challenge. 36
Although mass spectrometry-based glycoproteomics is a powerful platform for
large-scale profiling of glycoproteomes in cancers and other diseases, it typically
requires a good amount of samples, multiple steps for sample preparation, and the
commitment of a high performance instrument. In recent years, the lectin microarray
provides an alternative platform for sensitive and high-throughput profiling of protein
glycosylation.37,38 Lectins are immobilized on a glass slide to capture glycoproteins prelabeled with fluorophores through specific lectin-glycan interactions. Compared to mass
spectrometry, the lectin microarray enables rapid and direct analysis of crude samples,
which is especially appealing to high-throughput screening of differential glycan
patterns in clinical samples such as biofluids.37,39 However, in order for lectin binding,
glycoproteins cannot be denatured and thus cannot be detected using protein
antibodies because most antibodies require antigen to be denatured to expose epitopes
for the binding. As such, the lectin microarray is most useful for glycan pattern
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recognition instead of profiling of the entire glycoproteome. With the increasing
evidence that protein glycosylation plays a critical role in cancer onset and
progression,39-41 there is a definite need for a quick and effective glycoproteome
profiling platform for biomarker discovery and validation.
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CHAPTER 2.

SENSITIVE MEASUREMENT OF TOTAL PROTEIN PHOSPHORYLATION LEVEL
IN COMPLEX PROTEIN SAMPLES

2.1

Introduction

The following sections were reproduced with the permission from Royal Society of
Chemistry (Pan et al. 2015, Analyst 140, 3390-3396).
We present here a novel strategy to quantitatively measure total protein
phosphorylation level on a microwell plate, which features a multi-functionalized
chemical reagent termed pIMAGO. It is based on a polyamidoamine dendrimer that is
derivatized with titanium ions for its known superior selectivity towards phosphorylated
residues and with fluorophores for quantification.1-3 We have demonstrated the initial
applications of pIMAGO to analyze individual phosphoproteins.4-6 The measurement of
total phosphorylation level in biological samples presents distinctive technical
challenges due to sample complexity. Here, the specificity, sensitivity and quantitative
nature of the pIMAGO reagent for the measurement of the total phosphoprotein level
were examined with standard proteins and E. coli whole cell lysates. The pIMAGO
phosphorylation assay was then employed to measure the total protein phosphorylation
levels of multiple cell lysates and samples from human cell lines before and after
treatment. Finally, we showed that the technique can serve as a simple and useful tool
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to estimate the sample amount to be used for a typical phosphoproteomic analysis
using mass spectrometry.
2.2

Methods

2.2.1 Materials
All of the reagents for pIMAGO synthesis (except IRDye® 680 NHS ester,
obtained from LI-COR), protein dephosphorylation, kinase assay, cell lysis reagents,
trypsin, and all standard proteins were obtained from Sigma-Aldrich. Anti-phosphothreonine antibody was obtained from Cell Signaling Technology. Recombinant Syk
kinase was obtained from ProQinase. SnakeSkin dialysis tubing and Universal Nuclease
for Cell Lysis were obtained from Pierce. Sep-Pak C18 column was obtained from
Waters. All polyacrylamide gels, protein ladders, PVDF membranes, and other gelrunning supplies were obtained from Invitrogen. The 96-well microplates were obtained
from Corning. Cell culture reagents were obtained from Invitrogen. Jurkat cell lysates
(control and treated) were obtained from Cell Signaling Technology. HeLa cell lysates
(control and treated) were obtained from Abcam. E. coli BL-21 strain and MCF7 cell line
were generously provided by Dr. Robert Geahlen (Purdue). Yeast cells were generously
provided by Dr. Mark Hall (Purdue). Arabidopsis samples were generously provided by
Dr. Jian-Kang Zhu (Purdue). Purified Band 3 protein was generously provided by Dr.
Phillip Low (Purdue).
2.2.2 Synthesis of pIMAGO
IRDye® 680 NHS ester (LI-COR, Lincoln, NE), 1.5 mg (1 μmol) was first dissolved in
100 μL of DMSO and then supplemented with 400 μL of water and 400 μL of 300 mM
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HEPES (pH 7.7). The prepared dye solution was mixed with 70 μL of polyamidoamine
dendrimer generation 4 (PAMAM G4; Sigma-Aldrich) solution (~28 μmol amino groups
in 0.44 μmol dendrimer) provided as 10% (w/v) in methanol, and stirred overnight at
room temperature in the dark to functionalize the dendrimer with the dye (~2 dyes per
dendrimer). The solution was further mixed with 0.65 mg of 2-carboxyethyl-phosphonic
acid, 3 mg of N-hydroxysuccinimide (dissolved in 30 μl of water), and 30 mg of EDC (1ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) and stirred overnight at
room temperature in the dark to functionalize the dendrimer with phosphonic acid. The
reaction solution was dialyzed against water using SnakeSkin® pleated dialysis tubing
(3,500 MWCO, 22 mm dry diameter; Pierce). The reagent solution was transferred to a
dark tube and 11 μL of 10 M titanium oxychloride stock in 30% HCl was added. The
mixture was incubated for 1 hour with agitation at room temperature to chelate
titanium with phosphonic acid groups on the dendrimer. The final solution was again
dialyzed overnight against 0.05% HCl to remove any unbound titanium and stored at 4°C
for further use.
2.2.3 Preparations of Cell Lysates
E. coli cells (strain: BL21) were grown in 250 mL of Luria-Bertani (LB) medium
under shaking. At OD600 = 1.0, the cells were precipitated by centrifugation (10 min at
5,000 × g), washed, and stored at -80 °C. Cells were lysed in lysis solution (50 mM TrisHCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 1× protease inhibitor cocktail) for 30
min on ice. The cell debris was cleared at 14,000 × g for 10 minutes and the supernatant
containing soluble proteins was collected.
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Yeast cells were grown in 1 L of Yeast Extract-Peptone-Dextrose (YPD) medium
under shaking. At OD600 = 1.0, the cells were precipitated by centrifugation (5 min at
1,000 × g), washed, and stored at -80 °C. Cells were lysed in lysis solution (50 mM TrisHCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 1× protease inhibitor cocktail, 1
mM sodium orthovanadate, 1× phosphatase inhibitor cocktail, 10 mM sodium fluoride)
with glass beads under vigorous shaking for 30 min at 4 oC. The cell debris was cleared
at 14,000 × g for 10 minutes and the supernatant containing soluble proteins was
collected.
DG-75 cells were cultured in RPMI 1410 medium containing 10% fetal calf serum,
1% sodium pyruvate, 0.5% streptomycin/penicillin, and 0.05% β-mercaptoethanol.
MCF7 cells were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal
calf serum, 100 U/mL of penicillin, and 100 μg/mL of streptomycin. For PMA (phorbol12-myristate-13-acetate) treatment, MCF7 cells were treated with 200 nM PMA for 30
min after overnight serum starvation. Untreated cells were cultured under the same
conditions but treated instead with DMSO (dimethyl sulfoxide). DG-75 and MCF7 cells
were precipitated by centrifugation (5 min at 2,000 × g), washed, and stored at -80 °C.
Cells were lysed in lysis solution (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1%
NP-40, 1× protease inhibitor cocktail, 1 mM sodium orthovanadate, 1× phosphatase
inhibitor cocktail, 10 mM sodium fluoride) for 30 min on ice. The cell debris was cleared
at 14,000 × g for 10 minutes and the supernatant containing soluble proteins was
collected. For nuclease treatment, DG-75 cell lysates were further incubated with
Universal Nuclease for Cell Lysis (Pierce) at room temperature for 30 minutes and
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cleared again by centrifugation. For protein precipitation, DG-75 cell lysates (150 μL)
were mixed with cold acetone (600 μL) and incubated for 1 h at -20 °C. After
centrifugation for 10 min at 14,000 × g, the supernatant was discarded and the protein
pellet was air dried and then resuspended with 6 M urea and briefly sonicated.
The concentration of cell lysate was measured by the bicinchoninic acid (BCA) assay.
For mass spectrometry (MS)-based phosphoproteomic analysis, cell lysates were
denatured and reduced in 50 mM trimethylammonium bicarbonate containing 6 M urea
and 5 mM dithiothreitol for 30 min at 37 °C. The proteins were further alkylated in 15
mM iodoacetamide for 1 h in the dark at room temperature. The pH was adjusted to 8.0
and the samples were diluted 8 fold and digested with trypsin (at 1:100) overnight at
37 °C. Next day, the samples were desalted with a 100-mg Sep-Pak C18 column (Waters)
and vacuum dried. The resulting peptides were then enriched by PolyMAC method to
isolate phosphopeptides as described before.3
2.2.4 Measurement of Protein Phosphorylation by pIMAGO
Standard proteins (e.g. α-casein) and prepared cell lysates of interest were
immobilized onto a polystyrene 96-well microplate (Corning® 96-well EIA/RIA clear
polystyrene high binding microplate) at the designated amounts in each well in 100 μL
of carbonate buffer, pH 9.6, for either 2 h at room temperature or overnight at 4 oC.
The solution was removed then and the wells were washed three times with 200 μL of
the blocking buffer, 1% BSA (bovine serum albumin) in TBST (0.1% Tween-20, 150 mM
NaCl, 50 mM Tris-HCl, pH 7.5), and blocked with the same buffer for 1 h. Then, each well
was incubated with 0.5 μL of the pIMAGO reagent in 100 μL of 200 mM glycolic acid/1%
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trifluoroacetic acid solution for 1 h. After washing with 200 μL of 200 mM glycolic
acid/1% trifluoroacetic acid solution for three times and then with 200 μL of TBST for
three times, the wells were rinsed once with methanol and emptied. The plate was
scanned with an infrared imaging system (Odyssey® LI-COR, Lincoln, NE) and signals
were recorded. The protein phosphorylation levels of cell lysates of interest can then be
determined by interpolating from the α-casein standard curve established.
2.2.5 Phosphoprotein Dephosphorylation and In Vitro Kinase Assay
For phosphoprotein dephosphorylation, E. coli cell lysate was incubated with
CIAP (calf intestine alkaline phosphatase) in 1× CIAP buffer (50 mM Tris-Cl, 100 mM
NaCl, 10 mM MgCl2, 1 mM dithiothreitol) for 12 h at 37°C.
For in vitro kinase assay, 500 ng of purified Band 3 per well was immobilized
onto a polystyrene microplate and blocked as described above. The wells were then
incubated with 500 µM of ATP and 2 mM of MnCl2 with or without the presence of the
Syk kinase (50 ng per well). The kinase reaction was stopped with the addition of 200
mM glycolic acid/1% trifluoroacetic acid solution at the specified time points, and the
remaining reagents were washed away. Then, each well was incubated with pIMAGO,
and then washed, and detected as described above.
2.2.6 Preparations of Plant Samples
Arabidopsis thaliana seeds were cultured in liquid medium (half-strength murashige
and skoog salts and 1.5 % sucrose) with 24-h light at room temperature with shaking at
approximately 30 rpm for 12-day-old (seedling samples) or 28-day-old (mature
samples). Seedlings and mature samples were ground in lysis buffer (4% SDS, 0.1 M DTT
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in 0.1 M Tris-HCl, pH 7.5) and boiled at 95°C for 10 min. After centrifugation at 13,000 ×
g for 10 min, the supernatant was used for Filter Aided Sample Preparation (FASP) with
some modifications.7 Samples (400 µg) were loaded into a 30,000 MWCO FASP filter and
mixed with 200 µl of 8 M urea and then centrifuged at 13,000 × g for 15 min to remove
the flow-through. Proteins were alkylated in 30 mM IAA at 37°C for 1 h and centrifuged
again at 13,000 × g for 15 min to remove the flow-through. Proteins were washed with
200 µl of 8 M urea in 50 mM ammonium bicarbonate for three times, and digested with
trypsin in 50 mM ammonium bicarbonate (at 1:100) overnight at 37°C. Digested
peptides were eluted from the filter by 100 µl of 50 mM ammonium bicarbonate and 50
µl of 0.5 M NaCl, sequentially. The filtrate was collected by centrifugation at 13,000 × g
for 15 min, and combined, and desalted with a 100-mg Sep-Pak C18 column (Waters)
and vacuum dried. The resulting peptides were enriched by PolyMAC method to isolate
phosphopeptides as described before.3
2.2.7 LC-MS/MS Analysis
The eluted phosphopeptides were dried and resuspended in 10 μL of 0.5% formic
acid and injected into an Eksigent 2D Ultra nanoflow HPLC system. The reverse phase
C18 was performed using an in-house C18 capillary column packed with 5 μm C18 Magic
beads resin (Michrom; 75 μm i.d. and 30 cm of bed length). The mobile phase buffer
consisted of 0.1% formic acid in ultra-pure water with the eluting buffer of 100% CH3CN
run over a shallow linear gradient over 90 min with a flow rate of 300 nL/min. The
electrospray ionization emitter tip was generated on the prepacked column with a laser
puller (Model P-2000, Sutter Instrument Co.). The Eksigent Ultra HPLC system was
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coupled online with a high resolution hybrid linear ion trap Orbitrap mass spectrometer
(LTQ-Orbitrap Velos; Thermo Fisher). The mass spectrometer was operated in the datadependent mode in which a full-scan MS (from m/z 300-2000 with the resolution of
30,000) was followed by 20 MS/MS scans of the most abundant ions. Ions with charge
state of +1 were excluded. The mass exclusion time was 90 s. The LTQ-Orbitrap raw files
were searched directly against the corresponding database using a combination of
SEQUEST algorithm and MASCOT on Proteome Discoverer (Version 1.4; Thermo Fisher).
Peptide precursor mass tolerance was set at 10 ppm, and MS/MS tolerance was set at
0.8 Da. Search criteria included a static modification of cysteine residues of +57.0214 Da
and a variable modification of + 15.9949 Da to include potential oxidation of
methionine, and a modification of + 79.996 Da on serine, threonine or tyrosine for the
identification of phosphorylation. Searches were performed with full tryptic digestion
and allowed a maximum of two missed cleavages on the peptides analyzed from the
sequence database. False discovery rates (FDR) were set below 1% for each analysis.
Proteome Discoverer generates a reverse “decoy” database from the same protein
database, and any peptides passing the initial filtering parameters that were derived
from this decoy database are defined as false positive identification. The minimum
cross-correlation factor (Xcorr) filter was readjusted for each individual charge state
separately to optimally meet the predetermined target FDR of 1% based on the number
of random false positive matches from the reversed “decoy” database. Thus, each data
set had its own passing parameters.
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2.2.8 Absolute Quantification of Phosphorus Amount by ICP-MS
Samples were prepared for element analysis by inductively coupled plasma mass
spectrometry (ICP-MS) as instructed. Briefly, 10 mg of α-casein was weighed out and
dissolved in 9 mL of concentrated nitric acid overnight for complete digestion. The
digested sample was serially diluted using nanopure water until the final concentration
of nitric acid reached 2% w/v. A series of two-fold dilutions were further prepared using
nitric acid (2% w/v). ICP-MS analyses of samples were then performed at the Campuswide Mass Spectrometry Center (CWMSC), Purdue University, West Lafayette, IN.
2.3

Results and discussions

2.3.1 Design of pIMAGO strategy for measuring total protein phosphorylation level
The development of an efficient assay for measuring total protein
phosphorylation level in complex samples would be extremely useful for the field of
signal transduction. A reliable phosphorylation assay should be specific, sensitive,
quantitative, and can be readily calibrated using an affordable and common
phosphoprotein standard. The strategy we use to establish the assay features a recently
developed reagent, termed pIMAGO, which is based on a polyamidoamine dendrimer
functionalized to chelate multiple titanium ions on its surface for selective binding to
the phosphate groups on phosphorylated proteins and also with infrared fluorescent
dyes for sensitive detection and quantification (Figure 2.1A).4 The workflow of the
pIMAGO phosphorylation assay is similar to that of the classic enzyme-linked
immunosorbent assay (ELISA). As shown in Figure 2.1B, a complex protein sample such
as cell lysates is first immobilized onto a polystyrene 96-well microplate along with a
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phosphoprotein standard (e.g. α-casein) with known amounts ranging from 3 ng to 50
ng per well. The wells are then blocked with BSA and incubated with the pIMAGO
reagent, which binds to all phosphorylated proteins regardless of their sequences. After
washing away unbound pIMAGO, the microplate can be scanned using an infrared
imaging system (e.g. LI-COR Odyssey) and the fluorescent signal is recorded. A common
phosphoprotein, α-casein, at different known concentrations is used to construct a
calibration curve before each measurement.
2.3.2 Specificity and Sensitivity of pIMAGO-based Phosphoprotein Detection
The specificity and sensitivity of pIMAGO for phosphoprotein detection was first
examined using a number of standard phosphorylated and non-phosphorylated
proteins. As shown in Figure 2.2A, the pIMAGO fluorescent signals derived from 50 ng of
the phosphoproteins α-casein and β-casein were approximately 80- and 40-fold
stronger, respectively, than those from the non-phosphoproteins BSA and α-lactalbumin
of the same amount, with high reproducibility (shown as Mean + SD; CV% < 10%, n = 6).
The specificity was further demonstrated with E. coli cell lysates treated with or without
CIAP (calf intestine alkaline phosphatase). The phosphorylation signals from E. coli cell
lysates (containing 500 ng of proteins based on the bicinchoninic acid assay) decreased
significantly after the CIAP treatment to slightly above the background of the nonphosphoproteins, indicating that the pIMAGO signals were indeed due to protein
phosphorylation (Figure 2.2A).
Next, we investigated whether there were significant interferences from other
phosphate-containing molecules such as nucleic acids and phospholipids that may still
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remain in cell lysates, despite of the fact that the polystyrene microplates used in the
assay are intended to bind only large biomolecules as proteins and antibodies through
mainly hydrophobic interactions. Cell lysates of human cell line DG-75 were carefully
prepared per standard protocols and subjected to either nuclease treatment to degrade
all forms of DNA and RNA or protein precipitation using acetone to remove both
phospholipids and nucleic acids. DG-75 cell lysates with or without treatments were
then immobilized onto the plate and their phosphorylation levels quantified by
pIMAGO. As shown in Supporting Information Figure 2.3, neither nuclease treatment
nor protein precipitation resulted in any significant difference in total phosphorylation
levels of DG-75 cell lysates (with 500 ng of proteins per well). This indicates that the
potential interference from nucleic acids and phospholipids remaining in cell lysates are
trivial, probably due to the fact that pIMAGO preferably binds to phosphoproteins
rather than nucleic acids or phospholipids. In addition, polystyrene microplates likely
prefer to bind to proteins as well.
2.3.3 Quantitative Capabilities of pIMAGO-based Phosphoprotein Detection
Next, the quantitative capabilities of pIMAGO-based phosphoprotein detection
were evaluated. In order to relatively quantify the protein phosphorylation levels of
samples of interest, a calibration curve of a standard phosphoprotein needs to be
established first. We chose α-casein with its attractive features as a calibration standard:
commercially available with relatively low cost and stable phosphate content over more
than 6-month storage period. We also measured the absolute amount of phosphorus in
α-casein using inductively coupled plasma mass spectrometric (ICP-MS) analysis. The
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result showed that 1 ng of α-casein contained 1.06 pg of phosphorus (i.e. 0.106%
phosphorus by weight). Therefore, the assay can determine absolute phosphorus
amount in samples of interest indirectly after the calibration using known amount of αcasein. Quantitative detection of α-casein with two-fold serial dilutions ranging from 3
ng to 50 ng per well is shown in Figure 2.2B and Figure 2.4. Similarly, DG-75 cell lysates
with different protein amounts ranging from 30 ng to 500 ng were added to different
wells and detected with pIMAGO (Figure 2.2C). Both data resulted in excellent linearity
(r2 > 0.97). The outstanding quantitative capabilities of pIMAGO were further
demonstrated when it was employed to monitor an in vitro kinase assay. Band 3 is a
known protein substrate for spleen tyrosine kinase (Syk).8 Purified Band 3 (500 ng per
well) was immobilized onto the microplate and then after blocking, the wells were
incubated with Syk kinase (50 ng per well) for different lengths of time. As illustrated in
Figure 2.2D, pIMAGO was able to efficiently capture the increase in phosphorylation of
Band 3 over time. Altogether, these results demonstrated that pIMAGO can be used for
sensitive and quantitative measurement of phosphorylation change of individual
proteins or complex mixtures such as cell lysates in a straightforward format similar to
ELISA.
2.3.4 Detection of Total Phosphorylation Level Changes in Cell Lysates
Since pIMAGO is capable of quantitatively detecting protein phosphorylation
levels in cell lysates, it would be particularly useful to measure potential changes in total
protein phosphorylation levels upon treatment of cells. To evaluate whether the
perturbation of an upstream kinase would dramatically change the overall
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phosphorylation levels of cells, we selected three different human cell lines (Jurkat,
MCF7, and HeLa cells), treated with PMA (phorbol-12-myristate-13-acetate), a potent
activator of PKC (protein kinase C). PKC is involved in the regulation of a variety of
cellular functions including migration and polarity, proliferation, differentiation and
apoptosis, by directly phosphorylating substrates or activating downstream signaling
pathways.9,10 The established pIMAGO assay was employed to measure the
phosphorylation levels of cell lysates from Jurkat, MCF7, and HeLa cells, upon PMA
treatment (Figure 2.5). Interestingly, when compared to control lysates, stimulation by
PMA failed to result in significant increases in the total phosphorylation levels of Jurkat,
MCF7, or HeLa cell lysates using unpaired t-tests (Figure 2.5B and 2.5C). As a
comparison, Western blotting was performed using an anti-phospho-threonine
antibody, which also showed similar phosphorylation levels between control and PMAtreated cell lysates, although only of threonine sites (Figure 2.6). These results indicated
that a large portion of phosphoproteins in cells remained unchanged upon stimulation.
While the activation of an upstream kinase such as PKC would increase the
phosphorylation of a subset of downstream substrates and pathways, these effects may
not be strong enough to disturb the balanced steady state of equilibrium in overall
cellular phosphorylation level. We expect that with the emergence of the pIMAGO assay
capable of measuring total protein phosphorylation, more interesting studies will follow
up on the dynamics of overall phosphorylation level and its effects on cellular status.
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2.3.5 Use of pIMAGO Phosphorylation Assay for the Estimation of Starting Sample
Amount for Mass Spectrometry-based Phosphoproteomic Studies
Finally, we investigated whether the pIMAGO phosphorylation assay can serve as
a sensitive tool to help determine the sample amount required for a mass spectrometrybased phosphoproteomic analysis. Before performing a phosphoproteomic experiment,
it is important to estimate how much phosphorylation is in a test sample so that a
proper sample preparation protocol can be applied, including potential fractionations
and phosphopeptide enrichment.11-13 Samples like yeast and plant cell extracts are
typically lower in phosphorylation than human samples and thus increasing the starting
amount of yeast or plant samples for analysis is desirable for a global phosphoproteomic
profiling. However, there is no simple solution to estimate the starting sample amount
except performing a series of preliminary experiments, which can be both costly and
inefficient. Thus, we attempt to use the pIMAGO assay to measure total protein
phosphorylation level just as the bicinchoninic acid (BCA) assay measures protein
concentration.
To validate this idea, we have collected different types of samples from several
model organisms that are commonly used in mass spectrometry-based
phosphoproteomic analysis: human cell line DG-75, yeast, mature leaves and seedlings
of Arabidopsis (Arabidopsis thaliana). Cell lysates were carefully obtained as described
in Supplementary Information. The protein concentration of each cell lysate was first
measured by the BCA assay and then the pIMAGO phosphorylation assay was
performed to quantify the total protein phosphorylation level of each cell lysate (500 ng
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of proteins) by interpolating from the α-casein standard curve established in the same
experiment. As expected, DG-75 human cell lysate displayed much higher
phosphorylation level than yeast or plant samples, of which seedlings also showed
stronger phosphorylation than mature leaves (Figure 2.7). For example, 500 ng of DG-75
cell lysate has a total phosphorylation level equivalent to 38 ng of α-casein, while 500 ng
of yeast and seedlings are equivalent to 10 and 9 ng of α-casein, respectively, about one
fourth of that of DG-75. This also indicated that significantly more protein amount of
yeast or seedling cell lysate may be needed to achieve similar level of protein
phosphorylation of DG-75 cell lysate.
While the total phosphorylation level does not necessarily reflect the number of
phosphorylated proteins in a sample, it may be practically used to estimate total
phosphorylation numbers.13,14 We applied DG-75 cell lysates with different protein
amounts (10, 50, 100, and 300 μg) to a series of phosphoproteomic analyses under the
same instrument condition. The total number of unique phosphopeptides identified was
plotted against the starting protein amount. As shown in Figure 2.8A, the identification
number increased along with the protein amount where 100 μg of DG-75 cell lysate
resulted in an average of around 2500 unique phosphopeptides identified in a single LCMS/MS run with a total 90-min LC gradient. According to the pIMAGO phosphorylation
results, the total phosphorylation level of 400 μg of yeast or Arabidopsis seedling lysate
may be equivalent to that of 100 μg of DG-75 lysate. Therefore, 100 and 400 μg of yeast
and Arabidopsis seedling protein extracts were also applied to phosphoproteomic
analyses. As a result, an average of 1996 and 1821 unique phosphopeptides were
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identified from 400 μg of yeast and seedling lysates, respectively, doubling the number
of identifications when 100 μg of these samples were used under the same LC-MS/MS
condition.
2.4

Conclusions

In summary, we are reporting a novel phosphorylation assay on microwell plates
to measure total protein phosphorylation level in complex samples such as cell lysates.
The pIMAGO-based phosphorylation assay is sensitive, relatively simple and efficient for
specific and quantitative measurement of overall protein phosphorylation in an ELISAlike format. The technique can be employed to measure either total protein
phosphorylation levels of cell lysates calibrated to a phosphoprotein standard with
known concentration or global changes in phosphorylation levels of cell lysates upon
treatment. The assay can also serve as a useful tool to estimate the sample amount
required for a mass spectrometry-based phosphoproteomic analysis to ensure enough
phosphoproteins-containing samples are present. The new strategy has the potential to
become a routine analytical tool for general signal transduction and phosphoproteomic
studies.
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2.6

Figures

Figure 2.1 Schematic representation of the pIMAGO reagent.
(A) Schematic representation of the pIMAGO reagent. (B) Experimental workflow for
pIMAGO-based quantitation of total protein phosphorylation level in a complex protein
sample.
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Figure 2.2 Specificity and quantitative nature of pIMAGO-based phosphoprotein assay.
(A) Specific detection of protein phosphorylation from standard proteins and E. coli cell
lysates by pIMAGO. (B) Quantitation of fluorescent signals from pIMAGO-based
detection of the phosphoprotein standard α-casein (shown as Mean ± SD). (C)
Quantitation of fluorescent signals from pIMAGO-based detection of DG-75 cell lysates
(shown as Mean ± SD). (D) Quantitative measurement of fluorescent signals from
pIMAGO-based detection of phosphorylation of Band 3 by in vitro Syk kinase assay.
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Figure 2.3 . Investigation of potential interferences from other phosphate-containing
molecules such as nucleic acids and phospholipids that may remain in cell lysates.
Cell lysates of human cell DG-75 were subjected to either nuclease treatment to
degrade all forms of DNA and RNA or protein precipitation using acetone to remove
both phospholipids and nucleic acids. (A) Quantitation of fluorescent signals from
pIMAGO-based detection of the phosphoprotein standard α-casein (shown as Mean ±
SD). (B) Measurement of fluorescent signals from pIMAGO-based detection of DG-75
cell lysates with or without treatments (shown as Mean + SD). (C) The corresponding
fluorescence image scanned at 700 nm.

30

Figure 2.4 Quantitation of fluorescent signals from pIMAGO-based detection of α-casein
and DG-75 cell lysates.
Different amounts of α-casein with two-fold serial dilutions ranging from 3 ng to 50 ng
and DG-75 cell lysates ranging from 30 ng to 500 ng were immobilized and measured by
the pIMAGO phosphorylation assay. The fluorescence image was scanned at 700 nm.
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Figure 2.5 Detection of total phosphorylation level changes in human cell lysates by
pIMAGO phosphorylation assay.
(A) Quantitation of fluorescent signals from pIMAGO-based detection of the
phosphoprotein standard α-casein (shown as Mean ± SD). (B) Measurement of
fluorescent signals from pIMAGO-based detection of human cell lysates with and
without PMA treatment (shown as Mean + SD). (C) The corresponding fluorescence
image scanned at 700 nm.
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Figure 2.6 Detection of threonine phosphorylation of control and PMA-treated cells.
(A) Jurkat cell lysates (control and treated, 15 μL each) from Cell Signaling Technology,
(B) MCF7 cell lysates (control and treated, 20 μg each), and (C) HeLa cell lysates (control
and treated, 15 μL each) from Abcam were separated by SDS-PAGE, transferred onto a
PVDF membrane, and detected using an anti-phospho-threonine antibody (Cell Signaling
Technology).
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Figure 2.7 Quantitation of total phosphorylation levels of four cell lysates from three
model organisms commonly used in mass spectrometry-based phosphoproteomic
analysis by pIMAGO phosphorylation assay.
500 ng of proteins of each cell lysate was immobilized, measured, and interpolated to
the α-casein standard curve established.

34

Figure 2.8 Use of pIMAGO phosphorylation assay to estimate starting sample amount
for mass spectrometry-based phosphoproteomic analysis.
(A) Total number of unique phosphopeptides identified when different protein amounts
of DG-75 cell lysates were employed. (B) Total number of unique phosphopeptides
identified when different protein amounts of Arabidopsis seedling and yeast cell lysates
were employed (shown as Mean + SD).
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CHAPTER 3. MULTIPLEXED QUANTITATION OF PROTEIN EXPRESSION AND
PHOSPHORYLATION BASED ON FUNCTIONALIZED SOLUBLE NANOPOLYMERS

3.1

Introduction

The following sections were reproduced with the permission from ACS publishing (Pan
et al. 2012, Journal of the American Chemical Society, 134, 18201-18204).
Protein phosphorylation, one of the most ubiquitous post-translational
modifications, has been implicated in the regulation of almost all aspects of a cell’s life.
Aberrant phosphorylation dynamics within the cell contribute to the onset and
development of many malignances.1 Therefore, considerable effort has been devoted to
profiling protein phosphorylation under different cellular conditions. Currently, a
majority of studies report phosphorylation events that fail to distinguish changes in
phosphorylation from protein expression. Recent studies indicated that nearly 25% of
what appears to be differential protein phosphorylation is actually due to the changes in
protein expression.2 Thus, more accurate measurements of actual phosphorylation
changes normalized by protein expression changes are needed for the correct
interpretation of comprehensive phosphorylation dynamics. Traditionally, methods such
as Western blotting are used for the detection of specific proteins, including
phosphoproteins. While it is possible to detect phosphorylation and total protein signals
on the same blot by using two distinctive primary antibodies, it is often necessary to
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strip off the first primary antibody before the use of the second. This is not only timeconsuming, but also inevitably causes protein loss during the stripping process. Similar
to Western blotting, simultaneous quantification of phosphorylation and total protein
amount on microplates requires adding two primary antibodies sequentially into the
same wells of the microplate.3-5 This process also is troublesome due to the fact that i)
two primary antibodies from different sources are required (e.g., a phospho-specific
antibody from mouse and an antibody against the whole protein from rabbit); and ii)
binding of the first primary antibody to the target protein may prevent the second
primary antibody from reaching its epitope because antibodies are quite bulky (~150
kDa). Finally, all of these methods rely heavily on the availability and quality of
antibodies, which can be a major limitation, in particular for phospho-specific
antibodies.
In this study, we introduce a novel multiplexed assay for the simultaneous
quantitation of protein phosphorylation and total protein concentration on 96-well
microplates. The use of a multi-functionalized, water-soluble nanopolymer termed
“pIMAGO” (phospho imaging) and a protein antibody has allowed us to accurately and
quantitatively measure levels of protein phosphorylation normalized by protein amount.
3.2

Methods

3.2.1 Synthesis of pIMAGO
IRDye® 680 NHS ester (LI-COR, Lincoln, NE), 1.5 mg (1 μmol) was first dissolved in
100 μL of DMSO and then supplemented with 400 μL of water and 400 μL of 300mM
HEPES (pH 7.7). The prepared dye solution was mixed with 70 μL of polyamidoamine
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dendrimer generation 4 (PAMAM G4; Sigma-Aldrich) solution (~28 μmol amino groups
in 0.44 μmol dendrimer) provided as 10% (w/v) in methanol, and stirred overnight at
room temperature in the dark to functionalize the dendrimer with the dye (~2 dyes per
dendrimer). The solution was further mixed with 0.65 mg of 2-carboxyethyl-phosphonic
acid, 3 mg of N-hydroxysuccinimide (dissolved in 30 μl of water), and 30 mg of EDC (1ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) and stirred overnight at
room temperature in the dark to functionalize the dendrimer with phosphonic acid. The
reaction solution was dialyzed against water using SnakeSkin® pleated dialysis tubing
(3,500 MWCO, 22 mm dry diameter; Thermo Fisher). The reagent solution was
transferred to a dark tube and 11 μL of 10 M titanium oxychloride stock in 30% HCl was
added. The mixture was incubated for 1 hour with agitation at room temperature to
chelate titania with phosphonic acid groups on the dendrimer. The final solution was
again dialyzed overnight against 0.05% HCl to remove any unbound titania and stored at
4°C for further use.
3.2.2 Multiplex assay
Proteins such as BSA, catalase, α-lactalbumin, β-lactoglobulin, α-casein, β-casein,
recombinant Syk kinase, purified yeast protein Acm1, Syk-EGFP, and Syk-EGFP-NLS were
immobilized onto a polystyrene 96-well microplate at the designated amounts in each
well in 100 μL of carbonate buffer, pH 9.6, for either 2 h at room temperature or
overnight at 4 oC. The protein solution was removed and the wells were washed three
times with 200 μL of SuperBlock T20 blocking buffer (Thermo Fisher) supplemented with
1% BSA and blocked with the same buffer for 30 min. Then, each well was incubated
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with 0.5 μL of the pIMAGO reagent in 100 μL of 200 mM glycolic acid/1% trifluoroacetic
acid solution for 1 h. After further washing with 200 μL of 200 mM glycolic acid/1%
trifluoroacetic acid solution three times and then with 200 μL of SuperBlock T20
blocking buffer/1% BSA three times, primary protein antibody (at a concentration
optimized for each target protein) in 100 μL of blocking buffer was added into the wells
and incubated for 1 h. The wells were then washed three times with the blocking buffer
and incubated for 1 h with secondary antibody. After an additional three washing steps
with the blocking buffer, the wells were rinsed once with methanol and emptied. The
plate was scanned in an advanced infrared imaging system (LI-COR Odyssey®) with two
independent channels (emissions at 700 nm and 800 nm). To calculate the level of
phosphorylation normalized to the level of protein, the fluorescent signal derived from
bound pIMAGO (emission at 700 nm) was divided by that from bound protein
antibodies (emission at 800 nm).
3.2.3 Purification of Acm1
GST-Acm1 was over-expressed in E. coli, and cells were lysed with lysozyme and
sonication in buffer A (50 mM HEPES (pH 7.8), 250 mM NaCl, 0.1% Triton X-100, 5%
glycerol, 1 mM dithiothreitol) containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 1
μM pepstatin, and 100 μM leupeptin as previously described.6 Extracts were cleared by
centrifugation for 30 min at 35,000 X g and loaded onto a 1 mL GSTrap-HP column (GE
Healthcare). The column was washed with buffer A, and GST-Acm1 eluted with 10 mM
glutathione in buffer A. Fractions containing GST-Acm1 were pooled and dialyzed into a
25 mM HEPES (pH 7.8), 100mM NaCl and 40% glycerol solution. In-vitro kinase assay
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was performed to further phosphorylate purified GST-Acm1 with cyclin-dependent
kinase 1 (Cdk1) purified from yeast.7
3.2.4 Direct detection of Acm1 from E. coli lysate
Anti-GST monoclonal antibody from mouse (~1 μg per well) was first
immobilized onto a polystyrene 96-well microplate in 100 μL of carbonate buffer, pH
9.6, overnight at 4 °C. The antibody solution was removed and the wells were washed
three times with 200 μL of SuperBlock T20 blocking buffer (Thermo Fisher)
supplemented with 1% BSA and blocked with the same buffer for 30 min. The wells
were then emptied and incubated with E. coli lysate (containing ~10 μg of total protein)
over-expressing GST-Acm1 for 2 h at room temperature to allow GST-Acm1 to be
captured by the capture anti-GST antibody. Then, the pIMAGO reagent and a different
anti-GST antibody (polyclonal from rabbit) were consecutively applied to measure Acm1
phosphorylation and expression, as previously described in multiplex assay.
3.2.5 In-vitro auto-phosphorylation of recombinant Syk
Recombinant Syk kinase (ProQinase), 2 μg, was incubated with 500 μM of ATP in
1X NEBuffer for Protein Kinases (50 mM Tris (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 2
mM DTT, 0.01% Brij-35) for 1 hour at 30 °C. The final Syk kinase solution (50 ng/μL) was
stored at 4°C for further use.
3.2.6 Cell culturing
MCF-7 cells were cultured in Dulbecco’s modified Eagle’s medium containing
10% fetal calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. MCF-7 cell line
with tetracycline-regulated Syk-EGFP expression was constructed using T-Rex system
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(Invitrogen) previously.8 Cells were treated with 1μg/mL tetracycline for 24 hours to
induce Syk expression where indicated. MCF-7 cell line with stable Syk-EGFP-NLS
expression was generated by transfecting a Syk-EGFP-NLS encoded plasmid into a Sykdeficient MCF-7 cell line and selected by G418 treatment.9 TransIT-LT1 Reagent (Mirus)
was used for transfection. Briefly, TransIT-LT1 was warmed to room temperature and
vortexed gently; then 45 μL of TransIT-LT1 and 15 μg of pSyk-EGFP-NLS plasmid were
added into 1.5mL serum-free medium, mixed gently and incubated at room
temperature for 15 min. The mixture was added to cultured cells dropwise. After 24 h,
cells were selected by G418. Western Blotting and fluorescent microscopy were used to
examine the stable cell line. For hydrogen peroxide treatment, MCF-7 cells were treated
with 0.02% hydrogen peroxide for 10 min where indicated. Cells were lysed in RIPA
buffer (10 mM Tris (pH 7.5), 150 mM NaCl, 1% Na deoxycholate, 1% Triton x-100, 0.1%
SDS, 1mM Na Vanadate, 5mM EDTA, 10μg/mL each of aprotinin and leupeptin).
3.2.7 Syk immunoprecipitation from MCF-7 cells
Twenty μL (50% slurry) of GFP nanotrap agarose resin (Chromotek) was added to
the lysates and incubated for 4 h with end-to-end rotation at 4°C as previously
reported.10 After incubation, the beads/protein complex were thoroughly washed with
RIPA buffer (10 mM Tris (pH 7.5), 150 mM NaCl, 1% Na deoxycholate, 1% Triton x-100,
0.1% SDS, 1mM Na Vanadate, 5mM EDTA, 10μg/mL each of aprotinin and leupeptin) to
eliminate non-specific binding and Syk-interacting proteins. Bound Syk-EGFP was then
eluted with 100mM TEA (triethylamine) with vigorous shaking. The TEA in the eluate
was evaporated with speed vacuum and the remaining enriched Syk-EGFP was
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solubilized in carbonate buffer suitable for subsequent protein coating onto the
microplate.
3.3

Results and discussions

3.3.1 Design of pIMAGO-based multiplexed assay
In recent years, Titanium ions (IV) have been demonstrated to exhibit
outstanding selectivity toward binding phosphorylated residues.11-14 In our lab, we
successfully implemented a novel homogenous platform based on functionalized watersoluble nanopolymers in the form of dendrimers conjugated with multiple Titanium ions
(IV) for either phosphopeptide enrichment prior to mass spectrometric analyses or
phosphoprotein detection on microplates.7 Here, we further modify the dendrimer with
infrared (IR) fluorescent dyes to allow direct fluorescence detection with high sensitivity
and coupled with general antibody detection for unique applications in multiplexed
phosphorylation analyses (Figure 3.1A). Because of the much smaller size (~15 kDa) of
the pIMAGO reagent as compared to that of a typical antibody (~150 kDa), competition
for epitopes is reduced facilitating simultaneous detection of phosphorylation by
pIMAGO and total protein amount by protein antibody in the same well of a 96-well
microplate. Furthermore, the nanopolymer’s multiple functional groups per molecules
effectively amplify fluorescent signals and thus greatly improve the detection sensitivity
for low abundant phosphoproteins.
In this strategy, as illustrated in Figure 3.1B, proteins are first immobilized onto a
microplate. Then each well is incubated with the pIMAGO reagent for selective binding
to the phosphoamino acid residues on a phosphorylated protein. After washing away
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unbound pIMAGO, the primary antibody against the protein of interest is then added to
the same wells to bind to the target protein, both phosphorylated and
nonphosphorylated. Following further incubation and washing, a secondary antibody
linked with an infrared dye that emits at a wavelength (800 nm) different from the dye
on pIMAGO (700 nm) is added for fluorescence measurement. The final detection can
be achieved using an imaging system (e.g., LI-COR Odyssey®) equipped with two
independent channels (i.e., one for 700 nm emission, and the other for 800 nm
emission) for multiplexed detection.
3.3.2 Evaluation of pIMAGO-based multiplexed assay
We first examined the sensitivity and specificity of pIMAGO for phosphoprotein
detection using standard phospho- and non-phosphoproteins. When compared to 100
ng of the non-phosphoprotein bovine serum albumin (BSA), the signals generated from
the detection of the same amount of the phosphoprotein α-casein were about 40-fold
stronger, with high reproducibility (CV% < 10%, n=8; data not shown). The specificity
was further demonstrated with several nonphosphoproteins and phosphoproteins
treated with or without phosphatase (Figure 3.2). Next, the quantitative range of the
pIMAGO assay was demonstrated using standard phosphoproteins α-casein, β-casein,
and the phosphorylated yeast protein Acm1. Phosphoprotein levels could be quantified
with high accuracy over a range of three orders of magnitude. As one example,
quantitative detection of α-casein with serial dilutions ranging from 100 pg to 100 ng
per well is shown in Figure 3.3.
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We further explored the unique capability of the pIMAGO assay to quantify
phosphorylation with protein normalization using the phosphorylated yeast fusion
protein GST-Acm1. Following the scheme illustrated in Figure 3.1B, the pIMAGO reagent
was added to wells containing phosphorylated GST-Acm1 immobilized on the
microplate, followed by a further incubation with the primary anti-GST antibody in the
same well to bind to total immobilized GST-Acm1, regardless of its state of
phosphorylation. As shown in Figure 3.4A, the amount of phosphorylated GST-Acm1
detected by pIMAGO was proportional to the amount of immobilized GST-Acm1 protein.
Importantly, the phosphorylation signal after protein normalization remained the same
and was independent of the total amount of protein (Figure 3.4B, Figure 3.5). To further
demonstrate the capability of the method to analyze a protein in a sandwich ELISA
format, we coated the microplate with anti-GST monoclonal antibody from mouse to
capture GST-Acm1 expressed in E. coli lysate. Then the pIMAGO reagent and a different
anti-GST antibody (polyclonal antibody from rabbit) were consecutively applied to
measure Acm1 phosphorylation and expression simultaneously (Figure 3.6). These
results demonstrate the suitability of pIMAGO for use in multiplex assays to measure
the extent of protein phosphorylation normalized by protein concentration.
Currently, multiplex measurement of phosphorylation against protein expression
has been mainly performed using sets of two antibodies. We therefore performed
multiplex analyses in parallel comparing the pIMAGO assay to the dual antibody
method. We used spleen tyrosine kinase (Syk) as the model protein for the
measurements and a widely used antiphosphotyrosine antibody, 4G10, for the
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detection of the extent of tyrosine phosphorylation of Syk. Syk plays a crucial role not
only in adaptive immune receptor signaling but also functions as a tumor promoter in
many hematopoietic malignancies and as a tumor suppressor in highly metastatic breast
cancer and melanoma cells. A commercial active Syk was first immobilized onto a
microplate. The antiphosphotyrosine antibody 4G10 and the pIMAGO reagent were
then added to separate wells for the detection of Syk phosphorylation in a side by side
comparison. In the next step, an anti- Syk antibody was added to the each well to
measure the total amount of Syk protein. To evaluate whether the initial binding of
4G10 antibody or pIMAGO reagent would suppress the subsequent binding of the antiSyk antibody, a series of increasing concentrations of 4G10 antibody or pIMAGO reagent
were applied to the immobilized Syk. The signals derived from the reaction of the antiSyk antibody with Syk were then measured and compared. As shown in Figure 3.4C, the
signal from anti-Syk decreased sharply as a function of the amount of 4G10 antibody
added. Doubling the amount of 4G10 antibody resulted in a dramatic decrease in the
anti-Syk signal from 80% to 40% of the control (anti-Syk signal obtained in the absence
of 4G10 antibody or pIMAGO reagent). The inhibitory effect of 4G10 antibody on the
anti-Syk signal also was revealed by an incorrect assignment of the relative level of
protein phosphorylation when normalized for total protein level (Figure 3.4D). In
contrast, the pIMAGO reagent, whose molecular size is about 10 times less than that of
the 4G10 antibody, resulted in a much smaller inhibition of the subsequent binding of
anti-Syk antibody to the target protein over a broad range of concentrations (Figure
3.4C, Figure 3.4D).
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3.3.3 Measurement of differential Syk phosphorylation in MCF-7 cells
Finally, we applied the unique pIMAGO assay to measure differential
phosphorylation of a protein in a complex biological system. We chose three breast
cancer lines in which the amount of phosphorylated Syk could be modulated: MCF-7
cells lacking any Syk expression (Syk -/-), MCF-7 cells expressing exogenous Syk tagged
by enhanced green fluorescent protein (Syk-EGFP) and then treated with or without
trace hydrogen peroxide, and MCF-7 cells expressing exogenous Syk-EGFP with an
added nuclear localization signal (NLS) at the C-terminus (Syk-EGFP-NLS).9 The activity of
Syk is a reflection of its own phosphorylation status, so its accurate measurement is of
considerable interest. In cells expressing Syk-EGFP, the phosphorylation state of Syk can
be greatly enhanced by treatment with hydrogen peroxide, a phosphotyrosine
phosphatase inhibitor.15, 16 In cells expressing Syk-EGFP-NLS, the kinase also is highly
phosphorylated. To test whether the pIMAGO assay was capable of quantifying the
extent of tyrosine-phosphorylation of Syk-EGFP under these different cellular
conditions, we immunoprecipitated Syk-EGFP protein from lysates of MCF7 cells either
lacking Syk, expressing Syk-EGP and treated without or with hydrogen peroxide, or
expressing Syk-EGFP-NLS. The beads/protein complexes were thoroughly washed to
eliminate non-specific binding and Syk-interacting proteins. After elution, Syk-EGFP was
immobilized onto the microplate for the pIMAGO assay as described above. Samples
derived from MCF-7 cells lacking Syk (Syk -/-) served as a negative control (Figure 3.7A).
The level of Syk phosphorylation in the different cell states was calculated along with
protein normalization (Figure 3.7B). Treatment of Syk-EGFP-expressing cells with
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hydrogen peroxide significantly increased the amount of the Syk phosphorylation by ~10
fold, consistent with previous observations that Syk can be activated through hydrogen
peroxide induced oxidative stress in cells.15, 16 More interestingly, the extent of
phosphorylation of Syk-EGFP-NLS was found to be more than 60-fold higher than that of
Syk-EGFP, indicating a significantly enhanced kinase activity of Syk when localized to the
nucleus. This is interesting as it is thought that Syk localized to the nucleus represses
invasive tumor growth in breast cancer, most likely through the substrates that it
phosphorylates and regulates.17 Thus, the pIMAGO assay provides a powerful and
universal approach to quantify the extent of phosphorylation of a protein of interest
normalized against its level of expression in different cell states.
3.4

Conclusions

In conclusion, we have presented dendrimer-based water soluble nanopolymers
functionalized with Ti (IV) ions and infrared fluorescent tags. Coupled with general
antibody detection, the design led to unique applications in the simultaneous
measurements of protein expression levels and phosphorylation. The technique, in
theory, can measure absolute phosphorylation level on a protein provided that a
calibration curve using known amount of the protein and phosphorylation can be
constructed. Because it is difficult to construct such a calibration curve, the utilization of
the method will be most likely in measuring changes in protein phosphorylation under
different states. The technique may not be applicable to hyper-phosphorylated proteins
in which only a specific single site changes its phosphorylation status, thus not
significantly affecting overall phosphorylation level of the protein. The novel technique,
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however, is highly attractive to applications in which a good quality phospho-specific
antibody is not available. The ability to facilitate the finding of new kinase and
phosphatase substrates, screen kinase inhibitors, or profile changes in endogenous
levels of phosphorylation without site microenvironment prejudice or safety concerns
will be tremendously valuable for many research groups.
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3.6

Figures

Figure 3.1 Schematic representation of the pIMAGO reagent with fluorescent tags.
(A) A schematic representation of the pIMAGO reagent with fluorescent tags. (B)
Experimental workflow for pIMAGO assay for multiplexed detection of both
phosphorylation and protein concentration.
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Figure 3.2 Selective detection of phosphorylation signals by pIMAGO.
BSA, α-casein, catalase, α-lactalbumin, and β-lactoglobulin, 100 ng of each per well,
were immobilized onto the plate and measured by the pIMAGO assay. For the
dephosphorylation of α-casein, the specific well with immobilized α-casein was
incubated for 2 h with 4 μL of calf intestine alkaline phosphatase (CIAP) in 1 X CIAP
buffer at 30 °C before the pIMAGO assay. A) The fluorescence image scanned at 700nm
and B) the measurement of fluorescent signals from pIMAGO.
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Figure 3.3 Quantitation of fluorescent signals from pIMAGO detection of α-casein.
Different amounts of α-casein with serial dilution ranging from 100pg to 100ng were
immobilized onto the plate and measured by the pIMAGO assay. Phosphorylation signal
(after subtracting the 100ng of BSA background) and the amount of α-casein
immobilized were plotted on (A) a linear scale and (B) a log10 scale. Error bars are
standard deviations from the mean values of three experiments. (C) The corresponding
fluorescence image scanned at 700nm.
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Figure 3.4 Multiplexed detection of the phosphorylated Syk using pIMAGO or 4G10 and
anti-Syk antibody consecutively.
A) and B) Quantitative measurement of fluorescent signals for a yeast fusion protein,
GST-Acm1, phosphorylation and protein concentration; C) and D) pIMAGO and antiphosphotyrosine antibody (4G10) assay of Syk phosphorylation and protein
concentration.
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Figure 3.5 Quantitation of fluorescent signals from multiplexed detection of the
phosphorylated yeast fusion protein GST-Acm1 using pIMAGO and anti-GST antibody
consecutively.
Different amounts of GST-Acm1 with serial dilution ranging from 1ng to 100ng were
immobilized onto the plate and the pIMAGO multiplexed assay was performed.
Phosphorylation signal derived from bound pIMAGO was shown in red (for 700nm
emission) and protein signal derived from bound antibodies (anti-GST) was shown in
green (for 800nm emission).
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Figure 3.6 The sandwich format of multiplexed pIMAGO assay.
A schematic representation of the sandwich format of pIMAGO assay. Capture antibody
(shown in light blue) is first immobilized onto the plate. Protein complex (e.g. cell lysate)
is then applied to each well to allow isolation of target protein from protein complex.
The pIMAGO assay can then be performed as previously described. B) Infrared
fluorescence imaging of GST-Acm1 isolated from lysate of E. coli exogenously expressing
yeast protein GST-Acm1 by capture anti-GST antibody. See experimental procedure for
details. Lysate Acm1 indicates E. coli lysate expressing GST-Acm1. Lysate blank indicates
wild type E. coli lysate without GST-Acm1 as a negative control.
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Figure 3.7 Syk phosphorylation after protein normalization in different MCF-7 cells.
A) Infrared fluorescence imaging of Syk isolated from MCF-7 cells expressing exogenous
Syk-EGFP or Syk-EGFP-NLS; B) Syk phosphorylation after protein normalization in
different MCF-7 cells. See text for details.
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CHAPTER 4.

DEVELOPMENT OF POLYMER-BASED REVERSE PHASE GLYCOPROTEIN
ARRAY FOR CANCER BIOMARKER DISCOVERY

4.1

Introduction

Reverse phase protein array (RPPA) has recently advanced into a high-throughput
and cost-effective alternative to traditional sandwich immunoassays in which an
immobilized capture antibody is required for antigen capture and a second antibody
against a different epitope for detection.1 In RPPA, protein lysates are directly printed
onto the solid phase and then probed with a validated high-quality antibody that only
detects a specific target protein. Thus, RPPA provides expression data for a pre-specified
set of proteins across multiple tissue or cell lysate samples.2-4 Requiring very low
amounts of samples and being able to measure proteins of low abundances from sub-nL
amounts, RPPA is an emerging approach to profile protein expressions in normal or
diseased samples, particularly in clinical settings. Despite of the success, detection of
signaling molecules, more specifically post-translationally modified proteins, has been
very limited in RPPA assays.2,4,5 This primarily is due to low availability and low quality of
specific antibodies compared to those for total protein, and overwhelming number of
modified sites present with most not having any commercial antibodies. This problem is
even more evident in glycoproteomics, where glycoprotein antibodies are virtually
nonexistent.6 Moreover, the high complexity of tens of thousands of proteins in an
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unenriched mixture makes it extremely challenging to detect low abundant
glycoproteins.
In this study, we introduced a novel Polymer-based reverse phase Glycoprotein
Array (polyGPA) with nanopolymers functionalized with hydroxylamine groups to
covalently capture glycoproteins from whole protein extracts for detection on RPPA
platform using validated antibodies. The platform uses a similar procedure that is widely
implemented in standard RPPA platforms while maintaining extremely high sensitivity,
reproducibility, and adaptability for clinical validation. This strategy could become a
major technique for sensitive and reproducible pathway discovery and profiling and is
particularly appealing because there is virtually no commercial glycosite-specific
antibodies available, let alone being validated on the RPPA platform. polyGPA has the
potential to become a powerful tool for routine biomarker discovery and validation
studies. It also has possible future applications for diagnosis, prognosis, and analysis of
therapeutic efficacy using complex biofluids and tissue extracts.
4.2

Methods

4.2.1 Periodate Oxidation of Standard Glycoprotein
The standard, alpha-1-acid glycoprotein (AGP), was diluted to 1 mg/mL with
oxidation buffer (100 mM sodium acetate, pH 5.5), and oxidized with 10 mM sodium
periodate with shaking in the dark at room temperature for 30 min. The excess sodium
periodate was quenched by 50 mM sodium sulfite with shaking for 15 min. The oxidized
AGP was then denatured in 2% SDS and 2% 2-mercaptoethanol with boiling for 5 min.
Five-fold serial dilutions were made with 2% SDS in 100 mM sodium acetate, pH 5.5.
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4.2.2 Periodate Oxidation of Plasma
The human plasma was diluted to 5 mg/mL with oxidation buffer (100 mM
sodium acetate, pH 5.5), and oxidized with 10 mM sodium periodate with shaking in the
dark at room temperature for 30 min. The excess sodium periodate was quenched by 50
mM sodium sulfite with shaking for 15 min. The oxidized sample was then denatured in
2% SDS and 2% 2-mercaptoethanol with boiling for 5 min. Further dilutions were made
with 2% SDS in 100 mM sodium acetate, pH 5.5.
4.2.3 Periodate Oxidation of Microvesicles
The microvesicle pellet was first lysed with 2% SDS in 100 mM sodium acetate,
pH 5.5 and boiling for 10 min, and then oxidized with 10 mM sodium periodate with
shaking in the dark at room temperature for 30 min. The excess sodium periodate was
quenched by 50 mM sodium sulfite with shaking for 15 min. The oxidized sample was
then denatured in 2% SDS and 2% 2-mercaptoethanol with boiling for 5 min. Further
dilutions were made with 2% SDS in 100 mM sodium acetate, pH 5.5.
4.2.4 Reverse Phase Glycoprotein Array
Nitrocellulose membranes were incubated with the diluted reagent at 4 °C
overnight with shaking. The coated membranes were air-dried and ready for use. Serial
diluted samples were spotted on each membrane using a microarray printing pin
(Arrayit SMP15B). The membrane was washed with 4% SDS in TBST for three times and
TBST once for 5 min each wash and then blocked and probed with a validated primary
antibody and a corresponding secondary antibody with an infrared fluorophore. The
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membrane was scanned using an infrared imaging system (e.g. LI-COR Odyssey) and the
florescent signals were recorded.
4.2.5 Urinary Microvesicles Extraction
Urine samples were collected from healthy donors and bladder cancer patients,
and immediately centrifuged at 1,300 × g for 10 min at 4 °C. Supernatants were stored
at –80 °C. For the extraction of microvesicles, urine samples were thawed at 37 °C, and
then centrifuged at 4,000 × g for 10 min at 4 °C. Supernatants were centrifuged at
20,000 × g for 1 h at 4 °C and the microvesicle pellets were washed with ice-cold PBS
and centrifuged again at 20,000 × g for 1 h at 4 °C. The pellets were stored at –80 °C.
4.2.6 Preparations of Microvesicles for LC-MS/MS Analysis
The microvesicle pellets were lysed with 100 µL of 8 M urea in 100 mM Tris-HCl,
pH 8 for 10 min at 37 °C. The protein concentration was measured by the bicinchoninic
acid (BCA) assay. The proteins were reduced with 5 mM dithiothreitol for 30 min at
37 °C and then alkylated in 15 mM iodoacetamide for 1 h in the dark at room
temperature. The pH was adjusted to 8.0 and the samples were diluted 8 fold and
digested with trypsin (at 1:50) overnight at 37 °C. Next day, the samples were desalted
with a 50-mg Sep-Pak C18 column (Waters) and vacuum dried.
4.2.7 Enrichment of N-linked Glycopeptides
The desalted peptides were oxidized with 10 mM sodium periodate in 50% ACN,
0.1% TFA with shaking in the dark at room temperature for 30 min. The excess sodium
periodate was quenched by 50 mM sodium sulfite with shaking for 15 min. The samples
were then mixed with 50 μL of (50% slurry) hydrazide magnetic beads and incubated
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with vigorous shaking at room temperature overnight for the coupling reaction. The
magnetic beads were sequentially washed with 400 μL of 50% ACN, 0.1% TFA and 1.5 M
NaCl, three times per solution for 1 min per wash to remove non-coupled peptides. The
beads were then rinsed once with 100 μL of 1x GlycoBuffer 2 (NEB) and incubated with
3 μL of PNGase F (NEB) in 100 μL of 1x GlycoBuffer 2 at 37 °C for 2 h to specifically
release N-linked glycosite-containing peptides, which were then desalted by StageTip
and vacuum dried.
4.2.8 LC-MS/MS Analysis
The N-linked glycosite-containing peptides were resuspended in 10 μL of 0.1%
formic and injected into a Thermo Scientific Easy-nLC-1000 system. A 30-cm long C18
column with 75 μm i.d. was packed in-house with 2.2 μm C18 Pronto PEARL-120-2.2C18AQ resin. The mobile phase buffer A constituted 0.1% formic acid in ultra-pure
water, and buffer B contained 0.1% formic acid in 80% acetonitrile. The following
gradient was used in the LC-MS/MS experiment: the gradient changed from 6% to 30%
buffer B within 60 min, then from 30 to 50% buffer B within 10min; it was increased to
95% of buffer B within 5 min, followed by washing the column for 5 min. At the end, the
gradient was reduced back to 6% of buffer B and the column was equilibrated for 5min.
The flow rate of the UPLC was 200 nL/min. The electrospray ionization emitter tip was
generated on the pre-packed column with a laser puller (Model P-2000, Sutter
Instrument Co.). The Easy-nLC-1000 UPLC system was coupled online with a high
resolution hybrid linear ion trap orbitrap mass spectrometer (LTQ-Orbitrap Velos,
Thermo Fisher). The mass spectrometer was operated in the data-dependent mode in
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which a full-scan MS was followed by 10 MS/MS scans of the most abundant ions. Highresolution MS scans were acquired in the Orbitrap (30,000 FWHM at m/z 400) to
monitor peptide ions in the mass range of 350-1700 m/z, followed by collision-induced
dissociation MS/MS scans in the ion trap (isolation width 2 m/z, normalized collision
energy 35%) of the ten most intense precursor ions. Ions with unassigned charge state
as well as singly charged species were excluded. The maximum ion injection times of the
survey scan and the MS/MS scans were 500 ms and 50 ms, respectively and the ion
target values were set to 1E6 and 3E4, respectively. Selected sequenced ions were
dynamically excluded for 60 s. Data were acquired using Xcalibur software.
4.2.9 MS Data Analysis and Label-free Quantification
Mass spectra were analyzed using MaxQuant software version 1.5.3.28 using the
Andromeda search engine. The initial maximum allowed mass deviation was set to 6
ppm for monoisotopic precursor ions and 0.6 Da for MS/MS peaks. Enzyme specificity
was set to trypsin, and a maximum of two missed cleavages were allowed.
Carbamidomethyl cysteine was set as a fixed modification, N-terminal acetylation,
asparagine deamidation, and methionine oxidation as variable modifications. The
spectra were searched by the Andromeda search engine against the human Uniprot
sequence database (Homo sapiens, released on Jan, 2015) and 248 common
contaminants and concatenated with the reversed versions of all sequences. Protein
identification required at least one unique or razor peptide per protein group. The XIC
peak intensity and protein intensity was extracted by MaxQuant with match time
window of 1.5 min after retention time alignment. The required false positive rate was
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set to 1% at the peptide and 1% at the protein level, and the minimum required peptide
length was set to 6 amino acids. Contaminants, reverse identification and proteins only
identified by site were excluded from further data analysis. The peak intensity of each
LC-MS/MS analysis was transformed and normalized by subtracting the medians.
Missing values were imputed by random sampling from a generated narrow normal
distribution around the detection limit before statistical analyses were performed.
4.3

Results and discussions

4.3.1 Design of Polymer-based Reverse Phase Glycoprotein Array
In a regular RPPA, protein samples extracted from tissues or biofluids are
robotically spotted on an array such as nitrocellulose membrane array. An antibody is
then used to measure the amount of a particular protein present in the samples. The
setup allows hundreds of samples to be analyzed side by side in a single array. This
process is highly advantageous because only minimal amount of starting material is
needed, making it the ideal choice for clinical samples like needle biopsies, biological
fluids or microdissected tissues. The need for little material amount, sample-to-sample
comparison capabilities, and often sub-picogram sensitivity all contribute to the
recognition of the approach as a very powerful method. However, arguably the most
notable advantage of RPPAs from the technological point of view is the requirement of
only one validated detection antibody per target. Multiple studies have been carried out
to examine the quality of available antibodies. The consensus arising is that less than
20% of antibodies are of sufficient quality,7,8 and < 5% exhibit sufficient on-chip
performance or can be used for antibody pair matching.9-11 Many of them may display
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sufficient monospecific function in the initial testing, but in combination with multiple
antibodies and antigens exhibit significant cross-reactivity.12-15 Eliminating the need for
capture antibodies and antibody pairs in general has therefore advanced RPPAs as a
viable option for network signaling analyses, especially for clinical samples. Of course,
the method is still reliant upon a high-quality antibody capable of detecting only a single
target. This feat is certainly much easier to accomplish though, and already multiple
studies are available from the Human Protein Atlas project that validated over 1,000
detection antibodies suitable for array analysis.8,10,16 Taking advantage of this progress,
multiple studies have described the use of reverse phase arrays for clinical sample
analysis, including leukemia, breast cancer, prostate cancer studies and many others.1720

Despite the success, detection of glycosylated proteins in RPPA format has never
been done due to lack of glycoprotein-specific antibodies. Moreover, the high
complexity of thousands of proteins in an unenriched mixture makes it extremely
challenging to detect low abundant glycoproteins. Other forward microarray formats,
such as glycan or lectin arrays, have been extensively used for profiling of
glycosylation.21,22 However, glycan or lectin arrays typically are not applicable in RPPA
format due to relatively weak interactions leading to poor specificity, narrow lectin
binding affinities, and difficult downstream processing.23,24 Validated protein antibodies
are not utilized for detection because the samples cannot be denatured, thus
obstructing optimal antibody binding. As such, mass spectrometry or whole proteome
labeling has been used to identify the binding glycoproteins. With the increasing
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evidence that protein glycosylation plays a critical role in cancer onset and
progression,21,25,26 there is a definite need for a quick and effective glycoproteome
profiling platform for biomarker discovery and validation.
We propose here a new RPPA platform to capture and profile glycoproteome,
termed polymer-based reverse phase Glycoprotein Array (polyGPA), which is illustrated
in Figure 4.1. The first step is the immobilization of polyGPA on the nitrocellulose
membrane, thus enabling the capture of glycoproteome through covalent binding of
hydroxylamine on the dendrimer to oxidized hydroxyl groups on glycans to form the
oxime bond.27,28 The chemical conjugation step is instant, has very few side-reactions
under mild acidic condition, and occurs immediately during the printing process. The
captured denatured glycoproteins can then be detected using the same validated
antibodies as in standard RPPA, where any changes in signal can be attributed to
changes in overall glycosylation of the target. As with standard RPPA, sample source for
this analysis can be extensive, including cell lysates, cell fractions, tissues, membranes,
biofluids, biopsies, and others.
4.3.2 Specificity, Sensitivity and Quantitative Capabilities of polyGPA
To initially characterize the functionalized membrane array, we applied different
amounts of alpha-1-acid glycoprotein (AGP) in either natural or oxidized form. The
nanoliter volumes of the mixtures were spotted in dot-blot fashion onto the modified
membrane, and the AGP signal was detected using anti-AGP primary antibody and
fluorophore-functionalized secondary antibody. As a control, the identical spotting,
incubation and detection procedure was carried out with unmodified nitrocellulose
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membrane. The comparative results at the same detection intensity are shown in Figure
4.2A. As can be seen form the results, polyGPA-functionalized membrane displayed over
99% specificity in selecting oxidized form of AGP over the control, with good
quantitative linearity and reproducibility (Figure 4.2B). In addition, the sensitivity is
much stronger for polyGPA over standard RPPA (about 25-fold signal increase) for the
same protein amount. This is due to much improved orientation of the glycoprotein AGP
during binding to the polyGPA-coated membrane, exposing more antibody interaction
sites and thus increasing overall signal strength. This feature could be particularly
important during the analysis of low-abundant clinical samples.
4.3.3 Detection of Endogenous Glycoprotein in Plasma by polyGPA
We further demonstrated that polyGPA has extremely high binding capacity,
likely due to the derivatization of the surface with the nanopolymer that significantly
increases the surface binding area for glycoprotein capture in three dimensions.
Because of the high binding capacity and the ability to simplify the sample significantly
by enriching glycosylated proteins only, we can use much higher amount of starting
material than in a typical RPPA analysis. A typical starting sample limit for standard
RPPAs is 1 ug/uL due to platform binding capacity. With our new polyGPA, we can start
with much higher protein concentration, thus ensuring improved detection of lowabundant glycoproteins. For initial testing of polyGPA from very complex samples, we
utilized one of the most complex known samples – human plasma – and attempted to
detect endogenous AGP (Figure 4.3). We had to dilute the plasma sample down to 4
µg/µL to accommodate the upper limit binding capacity of standard RPPA. The data
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demonstrated easy detection of endogenous AGP from complex oxidized plasma
sample. On the other hand, the spotted sample with un-oxidized plasma did not
produce detectable signals. As in previous experiment, the signals produced by polyGPA
were significantly stronger than those from unmodified nitrocellulose membrane.
4.3.4 N-Glycoproteomics of Urinary Microvesicles from Bladder Cancer Patients
The true value of polyGPA would be demonstrated during its applications to
identify and validate disease biomarkers. While the majority of FDA-approved cancer
biomarkers are indeed glycoproteins,26 very little information is actually available in
terms of their glycosylation levels. Only a handful of biomarkers are currently detecting
protein glycosylation.6,29 As a prime example of this effort, monitoring glycosylation
level of serum has been reported to provide significantly better level of differentiation
for aggressive prostate cancer30 than the notoriously poor test on free PSA biomarker.31
With improved tools for glycoprotein profiling, this improtant PTM can become a major
source of disease biomarkers in the future.
Disease protein biomarker discovery and validation is a highly promising yet
incredibly challenging task.32 Many of the promising protein targets have found
applications in tumor biopsy screenings. However, biopsies are a highly invasive
procedure and typically offer very little sample material for processing. In addition, a
physiological tumor site would be already present for such an intervention, thus limiting
diagnostics timeline to later stage than desirable. As a result, “liquid biopsies” – analysis
of biofluids such as plasma, serum, and urine – have gained much attention as a likely
useful source of diagnostic biomarkers.
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In this study, we proposed to utilize human urine samples of healthy individuals
and those with bladder cancer for our bladder cancer biomarker discovery. However, it
is well know that biofluids have emmense dynamic range of proteins, with a few high
abundant proteins representing ove 90% of the mass. The expected glycoprotein
biomarkers of potential diagnostic value are most likely to be present in very low
abundance. To overcome sample complexity on the proteome scale, we isolated and
profiled cell-secreted extracellular vesicles (EVs). These typically include smaller size
exosomes derived from multivesicular endosome-based secretions, and microvesicles
derived from plasma membrane.33-35 Recent studies indicate that EVs are especially
critical for intercellular communication. As these are shed into virtually every biological
fluid and embody a good representation of their parent cells, analysis of the EV cargo
has a great potential for biomarker discovery and disease diagnosis. Interestingly,
researchers have found many differentiating characteristics of the cancer cell-derived
cargo, including gene mutations and active miRNA molecules with metastatic
properties.36-39 Particularly promising are the findings that these EV-based disease
markers can be identified well before the onset of symptoms or physiological detection
of a tumor, making them a promising candidate for early-stage cancer and other disease
detection. In addition, EVs are membrane-covered nanoparticles, which protects the
inside contents from external proteases and other enzymes.40,41 These features make
them highly stable in a biofluid for extended periods of time, a very valuable feature in a
diagnostic target. Despite some encouraging success in the analysis of exosomes and
microvesicles for DNA, RNA and protein content, the methods and data for examination
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of EV protein post-translational modifications is very limited. As glycosylation is a major
player in cancer and other disease progression, EV glycoproteins are active targets as
indicators of cellular states and for in vitro disease diagnosis.
Urinary microvesicles from healthy volunteers and bladder cancer patients from
IUSCC Tissue Bank (using 10 mL of urine for each sample) were extracted and subjected
to N-glycoproteomics as described in methods. From 8 independent single LC-MS/MS
runs of healthy control (n = 4) and bladder cancer samples (n = 4), Maxquant (version
1.5.3.28) identified a total of 1,214 unique glycosylation sites that are consistent with
the consensus motif N-X-S/T/C for N-linked glycosylation, where X is any amino acid
except proline. Among them, 1,095 glycosylation sites have localization probability
larger than 0.75, accounting for a total of 542 confident unique glycoproteins with 1%
FDR. These numbers are a significant improvement over anything previously published
for EVs (37 glycoproteins)42 or bladder cancer urine (53 glycoproteins from 800 mL of
urine).43 We believe this improvement resulted from optimized sample preparation
protocols for microvessicle extraction and glycopeptide enrichment. Using Perseus, we
were also able to quantify 733 unique glycosites from 378 glycoproteins, out of which
37 glycosites representing 26 glycoproteins were found significantly enriched in bladder
cancer samples with a ratio of at least 4-fold and p-value < 0.01 (Figure 4.4). These
differentially expressed glycoproteins in bladder cancer patients may serve as promising
biomarker candidates for bladder cancer (Table 4.1).
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4.3.5 Detection of Potential Bladder Cancer Biomarkers in Urinary Microvesicles by
polyGPA
Finally, we picked up a few biomarker candidates from the list (Table 4.1) to be
validated by polyGPA, including ceruloplasmin (CP), integrin alpha-M (ITGAM) and
mucin-4 (MUC4). Urinary microvesicles from healthy volunteers and bladder cancer
patients were validated by polyGPA as described in methods, using mono-specific
antibodies from Atlas Antibodies, where antibody specificity was validated on protein
arrays with a single peak corresponding to interaction only with its own antigen.
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4.5

Tables

Table 1 Glycosites Significantly Increased in Bladder Cancer.
Leading
proteins
G3V595
A0A0A0MSN4
P14384
P22792
A0A024R0K5

A0A024R0K5

A0A024R0K5

A0A024R0K5
A0A024R0K5;
A0A087X2E2;
P13688

Protein names
Alpha-1antichymotrypsin
Angiotensin-converting
enzyme
Carboxypeptidase M
Carboxypeptidase N
subunit 2
Carcinoembryonic
antigen-related cell
adhesion molecule 5
Carcinoembryonic
antigen-related cell
adhesion molecule 5
Carcinoembryonic
antigen-related cell
adhesion molecule 5
Carcinoembryonic
antigen-related cell
adhesion molecule 5
Carcinoembryonic
antigen-related cell
adhesion molecule 5;
Carcinoembryonic

Gene
names
SERPINA3
ACE
CPM
CPN2

Sequence window
EAEIHQSFQHLLRTLNQS
SDELQLSMGNAMF
TETSKILLQKNMQIANHTL
KYGTQARKFDVN
HDPHITKVIIPEKSQNFSAL
KKDILLPFQGQ
TSFTTLETRAFGSNPNLTKV
VFLNTQLCQFR

Positions within
proteins

Score

t-test pvalue

t-test
Difference

127;127

140.56 4.336131992

3.613533258

695;695;
121;121

131.52 2.090331552

6.090327382

384

131.62 2.092576169

5.274827242
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180.19

2.57403456

4.971019566

CEACAM5

LNVLYGPDAPTISPLNTSYRS
GENLNLSCHA

246;246

160.04 5.201145733

7.76858747

CEACAM5

SNITEKNSGLYTCQANNSAS
GHSRTTVKTIT

480;480;
302

129.42 7.139292312

7.523133874

CEACAM5

PRLQLSNGNRTLTLFNVTRN
DTASYKCETQN

204;204;382;
105;204

173.24 4.853514684

6.402467251

CEACAM5

DARAYVCGIQNSVSANRSD
PVTLDVLYGPDT

580;580;
402;224

193.51

4.158402443

CEACAM5;
CEACAM8;
CEACAM1

GQSLPVSPRLQLSNGNRTLT
LLSVTRNDVGP;
NQSLPVSPRLQLSNGNRTL
TLFNVTRNDTAS;

197;197;375;
98;197;197;
197;197

4.09513418

5.274044216
131.22 4.804514651
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antigen-related cell
adhesion molecule 8;
Carcinoembryonic
antigen-related cell
adhesion molecule 1

NQSLPVSPRLQLSNGNRTL
TLLSVTRNDTGP

Q8N6Q3

CD177 antigen

CD177

E9PFZ2

Ceruloplasmin

CP

X6RLJ0

P0C0L5

P0C0L5

E7ETN3

P02671

Complement C1q
subcomponent subunit A
Complement C4-B;
Complement C4 beta
chain; Complement C4-B
alpha chain; C4a
anaphylatoxin
Complement C4-B;
Complement C4 beta
chain; Complement C4-B
alpha chain; C4a
anaphylatoxin
Complement factor B;
Complement factor B Ba
fragment; Complement
factor B Bb fragment
Fibrinogen alpha chain;
Fibrinopeptide A;
Fibrinogen alpha chain

C1QA

MSIQGCVAQPSSFLLNHTR
QIGIFSAREKRD
GITYYKEHEGAIYPDNTTDF
QRADDKVYPGE
VIFDTVITNQEEPYQNHSG
RFVCTVPGYYYF

382;382

145.82 2.683630372

6.351862848

138;138

138.01 4.069436319

6.248418927

146;146

112.36

4.49634165

5.175643861

185.14 2.561444399

3.53071177

1328;1328;1328 162.93 3.839663795

3.521146774

C4B; C4A

GTWKISARFSDGLESNSST
QFEVKKYVLPNF

C4B; C4A

SAYWIASHTTEERGLNVTL
SSTGRNGFKSHA

CFB

HDFENGEYWPRSPYYNVS
DEISFHCYDGYTL

473;624;
122;122

105.52 3.012953872

3.298880458

FGA

GWLLIQQRMDGSLNFNR
TWQDYKRGFGSLND

686

160.82 2.970510505

2.866778851

226;226;226

76

77

P02675

Fibrinogen beta chain;
Fibrinopeptide B;
Fibrinogen beta chain

FGB

AGNALMDGASQLMGENR
TMTIHNGMFFSTYD

394;175
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Figures

Figure 4.1 Design and experimental workflow for polyGPA array.
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Figure 4.2 Specificity, sensitivity and quantitative capabilities of polyGPA.
(A) Specific capture and detection of glycoprotein standard AGP by polyGPA compared
to standard RPPA. (B) Quantitation of fluorescent signals from polyGPA-based detection
of AGP (shown as Mean ± SD).
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Figure 4.3 Detection of endogenous AGP in human plasma by polyGPA and RPPA.
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Figure 4.4 Statistically enriched glycosylation sites in bladder cancer samples identified
by permutation-based FDR-corrected t-test.
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